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Objectives: An important subset of patients with schizophrenia present clinically signiﬁ-
cant persistent negative symptoms (PNS). Identifying the neural substrates of PNS could
help improve our understanding and treatment of these symptoms. Methods:This study
included 64 non-affective ﬁrst-episode of psychosis (FEP) patients and 60 healthy controls;
16 patients displayed PNS (i.e., at least one primary negative symptom at moderate or
worse severity sustained for at least six consecutive months). Using voxel-based mor-
phometry (VBM), we explored for gray matter differences between PNS and non-PNS
patients; patient groups were also compared to controls. All comparisons were performed
at p< 0.05, corrected for multiple comparisons. Results: PNS patients had smaller gray
matter in the right frontal medial–orbital gyrus (extending into the inferior frontal gyrus)
and right parahippocampal gyrus (extending into the fusiform gyrus) compared to non-PNS
patients. Compared to controls, PNS patients had smaller gray matter in the right parahip-
pocampal gyrus (extending into the fusiform gyrus and superior temporal gyrus); non-PNS
patients showed no signiﬁcant differences to controls. Conclusion: Neural substrates of
PNS are evident in FEP patients. A better understanding of the neural etiology of PNS may
encourage the search for new medications and/or alternative treatments to better help
those affected.
Keywords: first-episode psychosis, persistent negative symptoms, magnetic resonance imaging, voxel-based
morphometry, neural substrates, frontal lobe
INTRODUCTION
In schizophrenia, negative symptoms are deﬁned as the absence
or diminution of normal behavior in the areas of affect (blunted
affect, anhedonia–asociality), speech (alogia), and goal-directed
behavior (avolition–apathy; Carpenter et al., 1988). Primary neg-
ative symptoms are considered intrinsic to schizophrenia while
secondary negative symptoms may occur in association with or
be caused by positive, depressive, or extrapyramidal symptoms
(from possible side effects of neuroleptic medications; Buchanan,
2007). Patients with enduring primary negative symptoms can be
classiﬁed as having deﬁcit syndrome (DS) or persistent negative
symptoms (PNS).
Brieﬂy, DS is typically assessed using the Schedule for Deﬁcit
Syndrome (SDS) (Kirkpatrick et al., 1989). The SDS assesses:
restricted affect, diminished emotional range, poverty of speech,
curbing of interest, diminished sense of purpose, and dimin-
ished social drive. At least two of these symptoms must be rated
“moderate” in severity or worse for 12 consecutive months to be
classiﬁed with DS. The SDS rules out secondary negative symp-
toms by assessing anxiety,medication effects, psychotic symptoms,
mental retardation, and depression. Finally, only those diagnosed
with a schizophrenia spectrum disorder can be classiﬁed with DS
(Kirkpatrick et al., 1989).
For a PNS classiﬁcation, as in our case, negative symptoms
must be present for at least six consecutive months with severity
assessed in terms of need for treatment (e.g., “moderate”or worse;
Buchanan, 2007). Classiﬁcation can be completed using any of
the accepted and validated negative symptom scales and does not
require the use of a speciﬁcally developed scale (like the SDS)
or access to extensive symptom history. Secondary negative symp-
toms are ruled out using any of the accepted and validated positive
symptom scales, depression scales, and extrapyramidal symptom
scales. PNS classiﬁcation is not diagnosis speciﬁc and is thought to
represent a broader concept than DS thus making it better suited
for clinical trials (Buchanan, 2007).
With modest epidemiological data available on PNS, preva-
lence in schizophrenia is estimated to be above 20% (higher than
that of DS; Buchanan, 2007). In fact, some ﬁrst-episode of psy-
chosis (FEP) studies reported a prevalence of severe or PNS at
23-40% (Malla et al., 2002, 2004; Makinen et al., 2008). With
increased severity of negative symptoms interfering with achieve-
ment of full remission (Andreasen et al., 2005) and negatively
impacting functional outcome (Milev et al., 2005), clinically sig-
niﬁcant PNS represent an unmet therapeutic need in many cases
(Kirkpatrick et al., 2006). Moreover effective drug treatments are
still not available (Goff et al., 1999; Heresco-Levy et al., 1999;
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Buchanan, 2007; Buchanan et al., 2007); however, newer, more
effective, treatments could be pursued based on more reliable and
consistent neurobiological substrates (Kirkpatrick et al., 2006).
In schizophrenia, negative symptom severity has been related
to changes in numerous brain regions including the frontal cortex
(Gur et al., 2000; Lacerda et al., 2007; Nesvag et al., 2009), tem-
poral cortex (Turetsky et al., 1995; Nesvag et al., 2009), thalamus
(Preuss et al., 2005), amygdala–hippocampal complex (Rajarethi-
nam et al., 2001; Yoshida et al., 2009), and ventricles (Andreasen
et al., 1982; Saijo et al., 2001). Results, however, are inconsistent
for some regions (temporal lobes, prefrontal cortex, and lateral
ventricles), some studies report an association between greater
gray matter loss and more severe negative symptoms but also the
opposite (more gray matter loss associated with improvement in
negative symptoms),while others report no signiﬁcant association
(Hulshoff Pol and Kahn, 2008). Moreover, no abovementioned
study controlled for secondary negative symptoms, so studying DS
or PNS exclusively could help reduce this confound and provide a
better understanding of primary negative symptoms (Buchanan,
2007).
Following this, Kirkpatrick and Buchanan (1990) hypothe-
sized that DS should involve a malfunction in the amygdala,
peri-amygdalar cortex, and prefrontal cortex circuitry (with the
same areas affected in PNS as the two sub-groupings are similar;
Buchanan, 2007). Since their hypothesis, several neuroimaging
studies have investigated differences between DS and non-DS
patients (see Table 1 for an exhaustive summary of the main ﬁnd-
ings). Very few studies have reported brain tissue differences that
reached statistical signiﬁcance; in those who did, right tempo-
ral lobe (Galderisi et al., 2008) and right ventricular (Quarantelli
et al., 2002) differences showed associations with primary negative
symptoms (or DS). Several studies however found negative results
for these same regions (right temporal lobe: Turetsky et al., 1995;
Quarantelli et al., 2002; right ventricle: Gur et al., 1994; Galderisi
et al., 2008). A more recent study by Cascella et al. (2010) com-
paring DS and non-DS patients using voxel-based morphometry
(VBM) reported robust reductions in gray matter in the DS group
bilaterally in the frontal and temporal lobes and in the right cin-
gulate cortex and left putamen. Although these important studies
provide guidance to the current one, it should be noted that the
DS/non-DS dichotomy is conceptually and empirically different
and more restrictive than the PNS/non-PNS classiﬁcation used
is this current investigation. Additionally, several confounds can-
not be excluded from these studies, like chronicity and long-term
medication effects. For example, increased volume in basal ganglia
structures but not amygdala–hippocampal complex has been asso-
ciated with prolonged antipsychotic exposure (Gur et al., 1998b;
Lieberman et al., 2001; Glenthoj et al., 2007).
To the best of our knowledge, there are no neuroimaging stud-
ies investigating PNS. UsingVBM, a fully automated technique,we
set out to explore gray matter differences between non-affective
FEP patients identiﬁed prospectively with PNS and those with-
out; these two groups were also compared with healthy controls.
Regarding our choice of brain structure exploration, there are sev-
eral advantages to using VBM: it avoids variance between raters,
which occurs when using manual segmentation of brain tissues, it
is easy and quick to analyze, and it is not dependent on a particular
hypothesis (Ashburner and Friston, 2001; Badcock et al., 2007). As
such,VBM represents a heuristic exploratory approach which can
lead to the generation of speciﬁc regions of interest. Examining
PNS in a ﬁrst-episode sample is more promising from a neurobi-
ological perspective to reveal potential neural substrates of these
enduring symptoms as medication and chronicity confounds are
better controlled for. Additionally, since we were studying people
early in the course of their illness, examining PNS over DS was
preferable since it is less restrictive (Buchanan, 2007). This char-
acteristic allowed us to identify a sub-group of patients which are
at risk of developing enduring negative symptoms based on the
available 1-year of clinical follow-up information. Although our
analysis was exploratory, we expected smaller gray matter in the
frontal and temporal regions in the PNS patients compared to the
non-PNS patients based on previous ﬁndings in DS (see Table 1).
MATERIALS AND METHODS
PARTICIPANTS AND TREATMENT SETTING
All patients were recruited and treated through the Prevention
and Early Intervention Program for Psychoses (PEPP-Montreal),
a specialized early intervention service at the Douglas Mental
Health University Institute in Montreal, Canada. People aged 15–
30 years from the local catchment area suffering from either
affective or non-affective psychosis who had not taken antipsy-
chotic medication for more than one month with an IQ above
70 were consecutively admitted as either in- or out-patients.
For complete program details see Malla et al. (2003) or visit
http://www.douglasresearch.qc.ca/pages/view?section_id= 165).
Those not meeting entry criteria were treated elsewhere and there-
fore not eligible for our neuroimaging study or any follow-up. For
the neuroimaging study, only patients aged 18 to 30 years with
no previous history of neurological disease or head trauma caus-
ing loss of consciousness were eligible. Furthermore, this study
was limited to those with non-affective psychosis. All clinical
evaluations were made by the trained clinicians working at the
PEPP-Montreal clinic as part of the clinic’s usual protocol, raters
were not aware of the subsequent PNS categorization.
In all, 64 non-affective FEP patients were subsequently sepa-
rated into two groups: PNS (n = 16, 25.0%) and non-PNS (n = 48,
75.0%). The criteria used for deﬁning PNS was adapted from both
Malla et al. (2004) and Buchanan (2007). PNS was deﬁned as
a global rating of moderate (3) or more on at least one neg-
ative symptom (affective ﬂattening, alogia, avolition–apathy, or
anhedonia–asociality) as measured with the Scale for the Assess-
ment of Negative Symptoms (SANS;Andreasen,1984a;Malla et al.,
2004; Buchanan, 2007). Additionally, as suggested by Malla et al.
(2004), if a score of 3 or greater was achieved on affective ﬂat-
tening and alogia entirely as a result of items inappropriate affect
and poverty of content of speech, respectively, such patients were
excluded from being classiﬁed with PNS. PNS patients had to
present with primary negative symptoms, that is, PNS patients had
to have a global rating of mild (2) or less on all positive symptoms
as measured with the Scale for the Assessment of Positive Symp-
toms (SAPS; Andreasen, 1984b; Buchanan, 2007), a total score of 4
or less on the Calgary Depression Scale for Schizophrenia (CDSS;
Addington et al., 1993;Malla et al., 2004; Buchanan, 2007), and low
levels of extrapyramidal symptoms [i.e., symptoms were absent
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Table 1 | Summary of neuroimaging results examining deficit syndrome schizophrenia.
Left hemisphere Right hemisphere
FRONTAL CORTEX
Buchanan et al. (1993)a DS>NDS DS>C NDS<C DS>NDS DS>C NDS<C
Turetsky et al. (1995)b DS<NDS DS<C NDS>C DS<NDS DS<C NDS>C
Sigmundsson et al. (2001)c DS<C* DS<C*
Quarantelli et al. (2002) DS>NDS DS<C* NDS<C* DS>NDS DS<C* NDS<C*
Galderisi et al. (2008) DS>NDS DS<C* NDS<C* DS>NDS DS<C* NDS<C*
Cascella et al. (2010) DS<NDS* DS<C* NDS<C* DS<NDS* DS<C NDS<C*
TEMPORAL LOBE
Turetsky et al. (1995)b DS<NDS DS<C NDS<C DS<NDS DS<C NDS>C
Sigmundsson et al. (2001)c DS<C*
Quarantelli et al. (2002) DS>NDS DS<C* NDS<C* DS>NDS DS<C* NDS<C*
Galderisi et al. (2008) DS>NDS DS<C* NDS<C* DS<NDS* DS<C* NDS<C*
Cascella et al. (2010) DS<NDS* DS<C* NDS<C* DS<NDS* DS<C* NDS<C*
CINGULATE CORTEX
Galderisi et al. (2008) DS>NDS DS<C NDS<C* DS>NDS DS<C NDS<C
Cascella et al. (2010)d DS<NDS*
CAUDATE
Buchanan et al. (1993) DS>NDS DS>C* NDS>C* DS>NDS DS>C NDS<C
Galderisi et al. (2008) DS<NDS DS<C NDS>C DS<NDS DS<C NDS>C
PUTAMEN
Sigmundsson et al. (2001)c DS>C*
Galderisi et al. (2008) DS<NDS DS>C NDS>C DS>NDS DS>C NDS>C
Cascella et al. (2010)d DS<NDS*
GLOBUS PALLIDUS
Sigmundsson et al. (2001)c DS>C*
Galderisi et al. (2008) DS<NDS DS>C NDS>C DS>NDS DS>C NDS>C
AMYGDALA-HIPPOCAMPUS
Buchanan et al. (1993) DS>NDS DS<C* NDS<C* DS>NDS DS<C* NDS<C*
HIPPOCAMPUS
Galderisi et al. (2008) DS<NDS DS<C NDS>C DS<NDS DS<C NDS<C
VENTRICLES
Gur et al. (1994)e DS=NDS DS=NDS
Quarantelli et al. (2002) DS<NDS DS=C NDS>C* DS<NDS* DS>C NDS>C*
Galderisi et al. (2008) DS<NDS DS>C NDS>C* DS<NDS DS>C NDS>C*
DS, deﬁcit syndrome patients; NDS, non-deﬁcit syndrome; C, healthy controls. The >, < and = signs indicate the numerical differences in brain volumes for each
study between two groups. Signiﬁcant differences marked with an asterisk. Signiﬁcant differences between DS and non-DS groups in bold. All results represent gray
matter differences except where noted.
aExamined parenchymal volume (gray and white matter) left side: DS>NDS∗, DS<C, NDS<C∗; right side: DS>NDS∗, DS<C, NDS<C∗; for white matter left side:
DS>NDS, DS<C, NDS<C∗; right side: DS>NDS∗, DS<C, NDS<C∗.
bExamined parenchymal volume only.
cOnly compared DS group to healthy controls using fully automated technique so only signiﬁcant results were presented.
dUsed fully automated technique so signiﬁcant results were only presented.
eDid not include numerical data for this comparison.
or too mild to require treatment with anticholinergic medica-
tion based on the Extrapyramidal Symptoms Rating Scale (ESRS;
Chouinard and Margolese, 2005)] (Malla et al., 2004; Buchanan,
2007). Finally, the abovementioned criteria had to be maintained
for a period of at least six consecutive months (between month 6
and 12 after admission, in our case; Malla et al., 2004; Buchanan,
2007).
Among the 48 non-PNS patients, nine displayed PNS but
were excluded from the PNS group because of clinically
relevant positive (n = 7) and depressive symptoms (n = 2);
none were excluded due to extrapyramidal symptoms. Diag-
noses for patients included: schizophrenia (PNS= 12; non-
PNS= 34), schizoaffective disorder (PNS= 3; non-PNS= 7),
schizophreniform disorder (non-PNS= 1), and psychosis NOS
(PNS= 1; non-PNS= 6) according to the Structured Clinical
Interview for DSM-IV (First et al., 1998) conﬁrmed between
two senior research psychiatrists (Ashok K. Malla and Ridha
Joober).
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Sixty healthy controls were recruited through advertisements in
local newspapers. Controls were included if they had no current or
past history of (1) any Axis I disorders [as assessed with the Struc-
tured Clinical Interview for DSM-IV-TR Axis I Disorders – Non-
patient Edition (First et al., 2007)], (2) any neurological diseases,
(3) head trauma causing loss of consciousness, or (4) a ﬁrst-
degree family member suffering from a schizophrenia spectrum
disorder. Controls were also chosen based on socio-demographic
variables (age, sex, and parental-socioeconomic status)matched to
all ﬁrst-episode patients participating in the neuroimaging study.
Upon entry to PEPP-Montreal, written informed consent was
obtained for all clinical and neurocognitive assessments done dur-
ing the 2-year program to be used in a longitudinal study of early
intervention in psychosis and to allow data from these assess-
ments to be used in subsequent studies. After a comprehensive
description of the present study, written informed consent was
obtained from all participants. The PEPP-Montreal protocol and
this researchprotocolwere approvedby theDouglasMentalHealth
University Institute Ethics Board and theMcGillUniversity Faculty
of Medicine Review Board.
SOCIO-DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
Negative and positive symptoms were assessed with the SANS
(Andreasen, 1984a) and the SAPS (Andreasen, 1984b), respec-
tively. Evaluators at PEPP have established an ICC of 0.89 on the
SAPS and 0.71 on the SANS; all raters participated in inter-rater
reliability sessions at least once a year to avoid rater drift. Depres-
sive symptoms were assessed with the CDSS (Addington et al.,
1993) and extrapyramidal symptoms with the ESRS (Chouinard
andMargolese, 2005). If prescribed,based on the ESRS and attend-
ing physician’s discretion, type and dose of anticholinergic taken
were recorded. The type and dosage of antipsychotic taken were
also recorded and subsequently converted into chlorpromazine
equivalents (Woods, 2003; Jensen and Regier, 2010). Only one
patient out of our sample was taking a typical antipsychotic and
only for the ﬁrst 2 months of treatment; all others were taking
atypical antipsychotics for the entire treatment period. Medica-
tion adherence, based on a 5-point scale ranging from 0 (never)
to 4 (fully), was obtained from patients or, when possible, from
family members; following a method validated elsewhere (Cas-
sidy et al., 2010). The abovementioned data were obtained at ﬁrst
assessment and at months 1, 2, 3, 6, 9, and 12 after ﬁrst assessment;
ﬁrst assessment was conducted, on average, within 1 month after
admission (in days; mean= 25.3, SD= 9.3, range= 4.8–51.0).
Finally, the following data were acquired at ﬁrst assessment: educa-
tion level (number of school years completed), Full Scale IQ with
the Wechsler Adult Intelligence Scale (Wechsler, 1997), parental-
socioeconomic status (SES) with the Hollingshead two-factor
index (Hollingshead, 1965), and handedness with the Edinburgh
Handedness Inventory (Oldﬁeld, 1971).
Among the three groups, age at scan, education level, and Full
Scale IQwere compared using a one-wayANOVA (post hoc Tukey’s
HSD test), parental SES with a Kruskal–Wallis H -test (post hoc
Mann–Whitney U -test), and gender and handedness with cross
tabulation and Chi-square tests. Between patient groups, indepen-
dent t -tests were used to compare antipsychotic dosage, symptom
totals, and duration of untreated illness and psychosis (DUI,DUP;
in weeks) and Mann–Whitney U -tests to compare medication
adherence at ﬁrst assessment, month 6, and month 12. Data on
CDSS and DUP were log-transformed while SAPS, antipsychotic
total dosage and DUI were square-root transformed to achieve
normal distribution; all other variables were normally distributed.
All analyses were conducted using SPSS version 12 (SPSS,Chicago,
IL, USA) and were two-tailed with a critical p-value of 0.05.
MRI DATA ACQUISITION AND ANALYSIS
Scanning was carried out at the MNI on a 1.5-T Siemens whole
body MRI system. Structural T1 volumes were acquired for each
participant using a three-dimensional (3D) gradient echo pulse
sequence with sagittal volume excitation (repetition time= 22ms,
echo time= 9.2ms, ﬂip angle= 30˚, 180 1mm contiguous sagittal
slices). The rectangular ﬁeld-of-view for the images was 256mm
(SI)× 204mm (AP). Patient groups did not differ as to when ses-
sions took place past entry (in weeks; PNS mean= 15.9, SD= 5.8;
non-PNS mean= 19.4, SD= 8.0; t = 1.63, df = 62, p= 0.11).
Structural T1 images were analyzed using VBM (Ashburner
and Friston, 2000; Good et al., 2001) using softwareVBM8 version
369 created by C. Gaser (http://dbm.neuro.uni-jena.de/vbm/).
First, the T1 images were normalized to a template space using
high-dimensional (DARTEL) spatial normalization and then seg-
mented into gray matter (GM), white matter (WM), and cere-
brospinal ﬂuid (CSF). After preprocessing, the resulting mod-
ulated images were smoothed with a 10-mm FWHM Gaussian
kernel. Gray matter (GM) volumetric differences were explored
among PNS patient, non-PNS patients, and healthy controls using
t -tests (PNS vs. non-PNS, PNS vs. controls, and non-PNS vs. con-
trols). Our main comparison focused on the patients that included
two contrasts:“non-PNS>PNS”and“PNS> non-PNS.”Our sec-
ondary comparisons included contrasts against healthy controls
that included the following: “control>PNS,” “PNS> control,”
“control> non-PNS”and“non-PNS> control.”All contrastswere
explored using a statistical threshold of p< 0.05, family wise error
corrected for multiple comparisons. Using the MNI coordinates
of the peak voxel(s) for signiﬁcant clusters, structures were iden-
tiﬁed using the automated anatomical labeling toolbox (Tzourio-
Mazoyer et al., 2002). Finally, whole-brain GM, WM, and CSF
volumes were estimated during the preprocessing for each par-
ticipant and were summed for an estimation of total intracranial
volume (TIV); the four volumes were compared among the three
groups using an ANOVA (post hoc Tukey’s HSD test).
RESULTS
SOCIO-DEMOGRAPHIC, PSYCHOPATHOLOGY, AND MEDICATION
See Tables 2 and 3 for values and statistical results. The three
groups did not signiﬁcantly differ on age, parental SES, gender, or
handedness. PNS and non-PNS patients together had fewer years
of education and a lower IQ compared to healthy controls; the
patient groups did not signiﬁcantly differ in education level or IQ.
As per design, PNS and non-PNS patients did not signiﬁcantly
differ on negative symptom total at ﬁrst assessment whereas PNS
patients had signiﬁcantly higher totals at month 6 and 12. Patient
groups did not signiﬁcantly differ on positive symptoms totals at
ﬁrst assessment or month 6 but did at month 12. The higher score
for the PNS patients at month 12 resulted from three patients
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Table 2 | Socio-demographic variables and brain tissue volumes.
PNS (n= 16) non-PNS (n= 48) Controls (n= 60) Statistic df p
SOCIO-DEMOGRAPHICVARIABLES
Age at scan (years) 24.2± 4.3 23.6± 3.4 24.8± 3.3 F = 1.61 2, 121 0.203
Parental SESa 3.4± 1.0 3.4± 1.2 3.1± 1.1 χ2 = 2.35 2 0.309
Educationb 11.2± 2.0 12.2± 2.6 14.4± 2.5 F = 16.78 2, 121 <0.001
Full scale IQc 97.6± 18.2 95.5± 12.9 107.9± 14.9 F = 10.1 2, 119 <0.001
Handedness 12 right 42 right 55 right χ2 = 3.31 2 0.191
Sex 13 male 33 male 40 male χ2 = 1.28 2 0.528
BRAINTISSUEVOLUMES (ml)
Gray matter 624± 56 642± 59 658± 71 F = 1.95 2, 121 0.147
White matter 605± 65 596± 62 618± 71 F = 1.46 2, 121 0.237
Cerebral-spinal ﬂuid 201± 27 198± 27 203± 35 F = 0.40 2, 121 0.673
Total intracranial 1430± 127 1436± 119 1479± 151 F = 1.65 2, 121 0.197
PNS, persistent negative symptoms.
aHollingshead parental-socioeconomic status: 1= highest and 5= lowest.
bEducation level measured as number of years completed; post hoc tests revealed: PNS= non-PNS (p= 0.298); PNS< controls (p< 0.001); non-PNS< controls
(p< 0.001).
cFull Scale IQ measured with theWechsler Adult Intelligence Scale (data were available for 58 healthy controls); post hoc tests revealed: PNS= non-PNS (p= 0.897);
PNS< controls (p= 0.037); non-PNS< controls (p< 0.001).
Table 3 | Clinical characteristics for PNS and non-PNS patients.
Clinical characteristics PNS (n= 16) non-PNS (n= 48) Statistic p
NEGATIVE SYMPTOMSTOTAL (SANS)
First assessment 31.2± 13.6 27.2± 12.4 t =−1.09 0.280
6-Month 30.1± 11.3 17.3± 12.0 t =−3.75 <0.001
12-Montha 30.1± 15.4 14.8± 10.0 t =−4.14 <0.001
POSITIVE SYMPTOMTOTAL (SAPS)
First assessmenta 34.5± 10.7 34.6± 17.7 t =−0.39 0.701
6-Montha 10.9± 9.2 9.5± 11.7 t =−1.39 0.173
12-Montha 16.4± 13.9 8.6± 11.7 t =−2.73 0.011
DEPRESSIVE SYMPTOMTOTAL (CDSS)
First assessmenta 3.7± 4.4 4.8± 5.2 t = 0.46 0.645
6-Montha 2.9± 3.5 1.7± 3.2 t =−1.62 0.111
12-Montha 1.6± 2.3 1.8± 3.2 t = 0.16 0.873
ANTIPSYCHOTIC DOSAGE (mg/DAY)b
First assessmenta 151.5± 116.1 173.0± 158.8 t = 0.12 0.908
6-Montha 174.8± 155.3 189.3± 151.2 t = 0.33 0.746
12-Montha 107.8± 61.4 203.5± 248.4 t = 1.36 0.178
MEDICATIONADHERENCEc
First assessment 3.3± 1.5 3.2± 1.5 U = 362.0 0.645
6-Month 3.1± 1.2 3.0± 1.4 U = 379.5 0.939
12-Month 2.3± 1.9 3.2± 1.5 U = 294.0 0.102
Duration of untreated illness (weeks) 409.6± 283.5 281.8± 250.7 t =−1.76 0.083
Duration of untreated psychosis (weeks) 37.2± 51.6 62.4± 84.4 t = 0.75 0.457
PNS, persistent negative symptoms.
aAnalyzed using transformed data but values are presented in raw form.
bAntipsychotic total presented in chlorpromazine equivalents.
cMedication adherence: 0= never adherent to 4= fully adherent.
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relapsing on several positive symptoms driving the group aver-
age higher; removal of these people produced similar group totals
(adjusted PNS mean= 11.5± 9.5; t =−1.50, df = 59, p= 0.14).
The patient groups did not signiﬁcantly differ on depressive symp-
tom totals at any time point. As well, there was no signiﬁcant
difference in total antipsychotic dosage (in chlorpromazine equiv-
alents); of note, PNS patients had a much lower total at month
12 (refer to Table 4 for a more detailed account of the antipsy-
chotic type and dosage taken by the patients over the 12-month
treatment period). The two groups did not differ in medication
adherence at any time point.
STRUCTURAL NEUROIMAGING (VOXEL-BASED MORPHOMETRY)
See Table 5 for all VBM results. The “non-PNS>PNS” contrast
revealed signiﬁcantly smaller GM in the right frontal medial–
orbital gyrus (extending into the inferior frontal gyrus) and right
parahippocampal gyrus (extending into the fusiform gyrus) in the
PNS patients relative to non-PNS patients (Figure 1); the opposite
contrast (“PNS> non-PNS”) revealed no signiﬁcant GM differ-
ences. For the contrasts with healthy controls, the“control>PNS”
contrast revealed signiﬁcantly smaller GM in the right parahip-
pocampal gyrus (extending to the superior temporal gyrus and
fusiform gyrus) in PNS patients compared to controls (Figure 2).
All other contrasts with controls revealed no signiﬁcant differ-
ences. Finally, there were no signiﬁcant between-group differences
regarding whole-brain GM, WM, and CSF volumes and TIV
(Table 2).
SUPPLEMENTARY ANALYSES
Although we were investigating a ﬁrst-episode sample to reduce
the effect antipsychotic medication exposure may have on brain
morphology, patients were scanned, on average, 18 weeks past
entry where all but three (two non-PNS and one PNS) had taken
antipsychotic medications. Therefore, we calculated a cumula-
tive antipsychotic dosage (in chlorpromazine equivalents) from
PEPP entry until scan weighted on medication adherence (PNS
mean= 458± 360; non-PNSmean= 674± 561; t = 1.44,df = 62,
p= 0.155) and re-analyzed the VBM using this as a covariate.
For our main contrast of interest (“non-PNS>PNS”) results
remained the samebutwith slightly different cluster sizes,p-values,
and t-values. For the peak voxels in each cluster, the right frontal
medial–orbital gyrus: cluster size= 2648, p-value< 0.001, and t -
value= 5.03; the right parahippocampal gyrus: cluster size= 997,
p-value= 0.023, and t -value= 5.01.
We also explored correlations between negative symptom totals
(at ﬁrst assessment, month 6, and month 12) and the GM volume
estimates from the regions found in the non-PNS>PNS con-
trast of the VBM analysis (critical p-value set at 0.016, 0.05/3).
We found a continuous relationship between parahippocampal
GM and severity of negative symptoms at month 6 (r =−0.459,
p< 0.001) and month 12 (r =−0.325, p = 0.009); trend-level
association at ﬁrst assessment (r =−0.273,p = 0.029). Conversely,
frontal GM did not show any signiﬁcant linear relationship with
negative symptoms at any time point.
A supplementary VBM analysis was performed using a more
lenient signiﬁcance threshold (p< 0.001, uncorrected) and we
found reduced GM in PNS patients compared to controls
in several frontal regions [anterior cingulate (cluster size= 36,
t = 3.31, p = 0.620); middle cingulate (cluster size= 44, t = 3.45,
p = 0.579); medial–orbital frontal gyrus (cluster size= 107,
t = 3.52, p = 0.372); and inferior orbital frontal gyrus (cluster
size= 25, t = 3.38, p = 0.687)].
DISCUSSION
This novel study examined the neural substrates of PNS using
VBM in a cohort of non-affective FEP patients. Previous studies
examined changes in brain structures associated with DS in peo-
ple with chronic schizophrenia using manual, semi-automated, or
fully automated techniques. The prevalence of PNS in our sam-
ple was 25% – in line with the suggested prevalence of over 20%
(Buchanan, 2007). Although DS and PNS differ on several aspects
(Buchanan, 2007), both are fundamentally based on enduring pri-
mary negative symptoms. Our study had an advantage over the
previous DS studies as our imaging data was acquired early on
in the patients’ treatment in an attempt to reduce the possible
effects of prolonged antipsychotic exposure on brain morphology
(Moncrieff and Leo, 2010); as well, we assessed the progression
of negative symptoms prospectively when categorizing the PNS
patients.
NEURAL SUBSTRATES OF PRIMARY NEGATIVE SYMPTOMS
Compared to non-PNS patients, PNS patients displayed signif-
icantly smaller gray matter (GM) volumes in the right medial–
orbital frontal gyrus extending into the inferior frontal gyrus.
These results are supported by one other study (also using VBM)
which found signiﬁcantly lower gray matter volume in the right
medial frontal gyrus in DS compared to non-DS patients (Cascella
et al., 2010); this study also found signiﬁcantly smaller clusters of
GM in the superior frontal gyrus bilaterally and the left middle
frontal gyrus. Previous studies investigating frontal cortex volume
as a whole did not report any signiﬁcant differences between DS
and non-DS patients (Buchanan et al., 1993; Turetsky et al., 1995;
Quarantelli et al., 2002; Galderisi et al., 2008). Moreover, one of
these studies reported smaller parenchymal (gray matter+white
matter) volume bilaterally in the in DS patients compared to non-
DS patients (Turetsky et al., 1995) while the other three reported
larger frontal lobe volume bilaterally in DS patients compared to
non-DS patients (Buchanan et al., 1993; Quarantelli et al., 2002;
Galderisi et al., 2008) – contrasting with the directionality of our
ﬁnding. Nonetheless, this is supported by the ﬁndings of Cascella
et al. (2010), which also used a VBM analysis and identiﬁed sig-
niﬁcant differences in more localized areas of the frontal cortex.
So, perhaps the neural substrates of primary negative symptoms
in relation to the frontal cortex are more localized rather than
encompassing the entire frontal area.
The PNS patients also displayed smaller GM in the right
parahippocampal gyrus extending into the fusiform gyrus com-
pared to non-PNS patients. This supported Cascella et al. (2010),
albeit in different clusters, who reported smaller GM in the right
inferior and middle temporal gyri and in the superior tempo-
ral gyrus bilaterally in DS patients compared to non-DS patients.
Although our study did not report the same peak clusters, we did
ﬁnd differences speciﬁc to Brodmann Area 20. Furthermore, fur-
ther examination of the ﬁgural result from Cascella et al. (2010)
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Table 4 |Types of antipsychotic medication for PNS and non-PNS patients.
First assessment PNS non-PNS PNS vs. non-PNS
(1st AP only)
1st 2nd 1st 2nd T p
Risperidone 2.2 (1.6) [8] – 1.9 (1.1) [17] – −0.58 0.568
Olanzapine 13.5 (3.8) [5] – 14.9 (6.8) [18] – 0.42 0.677
Seroquel 150.0 [1] – 325.0 (176.8) [2] –
Ziprasidone – – 80.0 [1] –
Paliperidone – – 3.0 (0.0) [2] –
Luxapac – – – 10.0 [1]
None [2] [16] [8] [47]
MONTH 1
Risperidone 2.3 (0.6) [8] – 2.2 (1.2) [16] 5.0 [1] −0.11 0.917
Olanzapine 12.5 (3.5) [5] – 13.8 (8.3) [19] 20.0 [1] 0.34 0.737
Seroquel 300.0 [1] – 300.0 (230.9) [4] 200.0 [1]
Ziprasidone – – 80.0 (0.0) [2] –
Paliperidone – – 3.0 (0.0) [2] –
Haloperidol – – 2.0 [1] –
Consta (2×/month) 25.0 [1] – 25.0 [1] –
None [1] [16] [3] [45]
MONTH 2
Risperidone 2.7 (1.6) [8] 0.5 [1] 2.1 (1.1) [15] 4.0 [1] −1.10 0.283
Olanzapine 10.5 (5.4) [5] – 11.5 (7.0) [20] – 0.30 0.770
Seroquel 300.0 [1] – 412.5 (193.1) [4] –
Ziprasidone – – 140.0 (28.3) [2] –
Paliperidone – – 3.0 [1] –
Haloperidol – – 1.5 [1] –
Consta (2×/month) 25.0 [1] – 31.3 (8.8) [2] 25.0 [1]
None [1] [15] [3] [46]
MONTH 3
Risperidone 2.2 (0.8) [8] – 1.9 (0.89) [15] 2.3 (2.5) [2] −0.69 0.501
Olanzapine 11.5 (7.6) [5] 2.5 [1] 11.6 (5.8) [19] – 0.03 0.980
Seroquel 450.0 [1] – 320.0 (164.3) [5] –
Ziprasidone – – 110.0 (70.7) [2] –
Paliperidone – – 3.0 [1] –
Haloperidol – – 1.5 [1] –
Consta (2×/month) 37.5 [1] – 31.3 (8.8) [2] 25.0 [1]
None [1] [15] [3] [45]
MONTH 6
Risperidone 2.4 (1.4) [7] 2.5 [1] 1.7 (0.9) [14] 3.0 (1.4) [2] −1.39 0.182
Olanzapine 3.8 (1.8) [2] 25.0 [1] 9.7 (5.2) [19] – 1.58 0.131
Seroquel 250.0 (70.7) [2] – 450.0 (244.9) [5] – 1.08 0.330
Ziprasidone – – 150.0 (42.4) [2] 40.0 [1]
Paliperidone 6.0 [1] – 6.0 [1] –
Haloperidol – – 1.5 [1] –
Consta (2×/month) 29.2 (7.2) [3] – 29.2 (7.2) [3] – 0.00 1.00
None [1] [14] [3] [45]
MONTH 9
Risperidone 2.1 (0.5) [6] 1.0 [1] 1.7 (0.7) [16] 2.0 (0.0) [2] −1.26 0.223
Olanzapine 3.8 (1.8) [2] – 8.9 (4.0) [12] 12.5 (10.6) [2] 1.74 0.107
Seroquel 325.0 (35.4) [2] – 414.3 (217.4) [7] – 0.55 0.598
Ziprasidone – – 120.0 [1] –
Paliperidone 3.0 [1] – 3.0 [1] –
(Continued)
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Table 4 | Continued
First assessment PNS non-PNS PNS vs. non-PNS
(1st AP only)
1st 2nd 1st 2nd T p
Haloperidol – – 1.5 [1] –
Consta (2×/month) 28.1 (6.3) [4] – 30.0 (68) [5] – 0.42 0.685
None [1] [15] [5] [44]
MONTH 12
Risperidone 2.0 (0.6) [7] – 1.8 (1.2) [15] 2.1 (0.6) [4] −0.39 0.701
Olanzapine 3.8 (1.8) [2] – 7.8 (4.3) [12] 5.0 [1] 1.29 0.221
Seroquel – – 483.3 (194.1) [6] 316.7 (275.4) [3]
Ziprasidone – – 100.0 [1] –
Paliperidone – – 3.0 (0.0) [2] –
Haloperidol – – 15 [1] –
Consta (2×/month) 29.2 (7.2) [3] 37.5 [1] 28.6 (6.1) [7] – −0.14 0.896
Consta (3×/month) 25.0 [1] – – –
None [1] [15] [6] [40]
Table 5 | Gray matter differences among PNS patients, non-PNS patients, and healthy controls using voxel-based morphometry.
Cluster size p-value (FWE) t -value MNI coordinates Side Region or structure (BA)
x y z
NON-PNS>PNS
1802 0.004 4.96 3 54 −12 Right Medial–orbital frontal gyrus (BA 11)
4.39 17 51 −5 Right Medial–orbital frontal gyrus (BA 10)
3.80 14 41 −15 Right Inferior frontal gyrus (BA 11)
926 0.05 4.94 35 −19 −30 Right Parahippocampal gyrus (BA 36)
4.21 39 −33 −17 Right Fusiform gyrus (BA 20)
PNS>NON-PNS
No signiﬁcant differences
CONTROL>PNS
2322 0.002 4.93 35 −16 −30 Right Parahippocampal gyrus (BA 36)
4.64 39 −31 −17 Right Fusiform gyrus (BA 20)
4.24 50 −28 4 Right Superior temporal gyrus (BA 22)
PNS>CONTROL
No signiﬁcant differences
CONTROL>NON-PNS
No signiﬁcant differences
NON-PNS>CONTROL
No signiﬁcant differences
MNI coordinates represent the peak voxels in each cluster where x, y, and z indicate the distance measured in millimeters from the anterior commissure in the
sagittal, coronal, and axial planes, respectively. BA represents the Brodmann Area for each region or structure.
revealed differences in the temporal area extended into themedial–
temporal lobe (including the parahippocampal cortex bilaterally),
although no signiﬁcant peak was identiﬁed within these regions.
Of the previous studies investigating temporal lobe volume as a
whole, only one study identiﬁed a signiﬁcantly smaller volume on
the right side in DS patients compared to non-DS patients but
not in the left side (Galderisi et al., 2008); the other two stud-
ies reported numerically smaller (Turetsky et al., 1995) and larger
(Quarantelli et al., 2002) volumes in the DS patients compared
to non-DS patients. So, the neural correlates of primary negative
symptoms in relation to the temporal lobe appear to be more lat-
eralized toward the right side that may be related to the lobe as a
whole or to more speciﬁc clusters therein; more studies are needed
to lend support and expand upon this.
Finally, when compared to a matched sample of healthy sub-
jects, the non-PNS patients showed no signiﬁcant GM differences.
Frontiers in Psychiatry | Frontiers in Neuropsychiatric Imaging and Stimulation May 2012 | Volume 3 | Article 42 | 8
Benoit et al. Imaging persistent negative symptoms FEP
FIGURE 1 | Gray matter differences between PNS and non-PNS
patients. Voxels where signiﬁcant group differences were observed
are depicted in color and are superimposed on aT1 MRI template
image. The highlighted areas indicate smaller gray matter volume in
PNS patients compared to non-PNS patients at a signiﬁcance level of
p< 0.05, cluster corrected. (A) Shows the right medial frontal gyrus
result; (B) shows the right parahippocampal/fusiform gyrus result. The
location of the eight coronal and axial slices are illustrated on the
sagittal planes with coordinates presented in MNI space. The color bar
indicates the t-value.
FIGURE 2 | Gray matter volume differences between PNS
patients and controls. Voxels where signiﬁcant group differences
were observed are depicted in color and are superimposed on aT1
MRI template image. The highlighted areas indicate smaller gray
matter volume in PNS patients compared to non-PNS patients at a
signiﬁcance level of p< 0.05, cluster corrected. Shown here is the
right parahippocampal gyrus/superior temporal gyrus result. The
location of the 8 coronal and axial slices are illustrated on the sagittal
planes with coordinates presented in MNI space. The color bar
indicates the t-value.
On the other hand, the PNS patients, compared to the healthy
subjects, showed smaller GM in the right parahippocampal gyrus
extending into the fusiform gyrus and superior temporal gyrus
(almost this exact cluster was identiﬁed when compared to the
non-PNS patients). One other study found signiﬁcantly smaller
GM in the parahippocampal gyrus, albeit on the left side, in DS
patients compared to controls (Sigmundsson et al., 2001). Three
other studies found signiﬁcantly smaller GM in the temporal
lobe bilaterally in DS patients compared to controls (Quarantelli
et al., 2002; Galderisi et al., 2008; Cascella et al., 2010). In the
DS patients, one other study reported signiﬁcantly smaller GM
in the middle temporal gyrus bilaterally (Cascella et al., 2010)
while the other two reported smaller volume in the temporal
lobe as a whole (Quarantelli et al., 2002; Galderisi et al., 2008).
Together, these ﬁndings suggest that smaller GM in the temporal
lobe appear to be a substrate of non-affective psychosis (namely
schizophrenia) with a strong relationship to primary negative
symptoms.
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Overall, our results showed localized GM differences in the
rightmedial orbitofrontal and rightmedial–temporal areas related
to PNS which are observable early on in the course of treat-
ment. Moreover, there were no global GM differences among
patients with PNS, patients without PNS and control subjects.
Therefore, speciﬁc frontotemporal variations appear to be associ-
ated with persistent primary negative symptoms in non-affective
FEP patients partially supporting the original hypothesis put for-
ward by Kirkpatrick and Buchanan (1990) that associated DS with
variations in the amygdala, peri-amygdalar, and prefrontal cor-
tex circuitry (Kirkpatrick and Buchanan, 1990). While our results
implicated the prefrontal cortex with PNS, we did not ﬁnd sup-
port for an association with the peri-amygdaloid or amgydaloid
area. However, GM differences were identiﬁed in the parahip-
pocampal gyrus – a region that is known to have strong con-
nections with the peri-amygdaloid and amygdaloid area (Majak
and Pitkanen, 2003). Moreover, the orbital frontal cortex along
with sub-cortical regions including the amygdala–hippocampal
area has been suggested to mediate negative symptoms (Zald and
Kim, 2001).
Regarding the frontal area, previous studies have reported
smaller GM volumes to be correlated with greater severity of nega-
tive symptoms. More speciﬁcally, these studies found associations
with GM volume in the right inferior frontal opercular and tri-
angularis (Berge et al., 2011), left straight gyrus (Szendi et al.,
2006), and the orbitofrontal (Baare et al., 1999) – the region we
identiﬁed to be smaller in the PNS patients compared to the non-
PNS patients. On the other hand, regarding the medial–temporal
lobe, several studies have related GM volume to negative symp-
toms as well (Gur et al., 1998a; Anderson et al., 2002; Bodnar et al.,
2011). These results together suggest a strong relationship between
frontal and medial–temporal GM and negative symptoms but the
relationship appears stronger with the frontal region. To examine
this further we performed correlations between negative symptom
totals (at ﬁrst assessment, month 6, and month 12) and the GM
volume estimates from the medial–orbital frontal and parahip-
pocampal regions. Only parahippocampal GM was signiﬁcantly
correlated with the severity of negative symptoms at month 6 and
month 12 (with a trend-level result at ﬁrst assessment), which may
be indicative of a distinct neurobiological difference between PNS
and non-PNS patients.
TREATING PNS
People with PNS have beneﬁted from treatments like cognitive
behavioral therapy (Rector et al., 2003; Turkington et al., 2008)
and loving-kindness mediation (Johnson et al., 2009) in reduc-
ing negative symptoms. However, for those resistant to such
treatments, alternatives must be considered like cognitive reme-
diation or transcranial magnetic stimulation (TMS), for exam-
ple. Both the frontal and temporal cortex could be targeted in
pharmaco-fMRI research (Stein,2001;Honey andBullmore,2004)
to help identify new medications to better treat negative symp-
toms than the currently used agents like d-cycloserine or glycine
that have produced somewhat inconsistent results (Goff et al.,
1999; Heresco-Levy et al., 1999; Buchanan et al., 2007). This study
suggests that the frontotemporal circuitry might be related to
PNS and should be explored further as regions of interest in the
development or implementation of future treatment options such
as those.
LIMITATIONS
There are several limitations in our study. First, although we
employed a ﬁrst-episode sample in an attempt to reduce the effect
of antipsychotic exposure on brain morphology (Moncrieff and
Leo, 2010), the majority of patients were still treated with antipsy-
chotics possibly affecting our results. Our main results did not
change after re-analyzing the data including a cumulative antipsy-
chotic covariate; however, examining antipsychotic naïve patients
would be best to remove any effects. Second, avolition and anhe-
donia were more prevalent than alogia and affective ﬂattening in
our sample and, as such, our results may not be generalizable to all
negative symptoms. Furthermore, the categorical approach of this
study did not allow us to specify which negative symptoms con-
tributed the most to the structural differences identiﬁed; future
studies need to examine these symptoms separately. Third, we
did not ﬁnd any structural differences in the frontal area which
has been a hallmark in studies examining schizophrenia (Shen-
ton et al., 2001; Williams and Castner, 2008). This may have been
due to the conservative statistical threshold (p< 0.05, family wise
error corrected for multiple comparisons) we used in order to
limit the chances of false positives in our VBM results. Never-
theless, when lowering our threshold (p< 0.001, uncorrected),
we found reduced GM in PNS patients compared to controls in
the anterior cingulate, middle cingulate, medial–orbital frontal
gyrus, and inferior orbital frontal gyrus. These are interesting
ﬁndings but the identiﬁed clusters were very small and p-values
indicated a high probability of false positives. Fourth, the inter-
rater score measured for the SANS is quite low (0.71) although
similar to what was reported in a previous study of compar-
ative inter-rater reliability (Norman et al., 1996). Fifth, at the
time of analysis, clinical data was only available for the ﬁrst 12
months of treatment in our sample; however it has been previ-
ously shown that PNS categorization is more consistent after the
ﬁrst year of treatment (Chang et al., 2011). In our sample we
have used data from the last 6 months of treatment to limit the
possible effects of the instability of symptoms but it would be
interesting to re-evaluate the categorization with longer follow-
up period. Sixth, the PNS classiﬁcation being relatively new is
evaluated following a set of guidelines rather than a consen-
sus deﬁnition, which has yet to be developed. For example, the
guidelines recommend PNS categorization to be given if negative
symptoms are of moderate severity or worse (Buchanan, 2007),
which can be based on a global rating or on ratings for speciﬁc
symptoms. Lastly, our PNS patient group was relatively small,
limiting the generalization (interpretation) of our results. Addi-
tionally, we could not examine whether the structural differences
related to PNS were speciﬁc to one diagnosis or not because we
were limited by the small number of patients with PNS that did
not allow for any meaningful diagnosis speciﬁc between-group
comparisons.
CONCLUSION
The current study identiﬁed smaller graymatter in the right frontal
and temporal cortices in non-affective FEP patients with PNS
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compared to patients without PNS. Compared to controls, we also
identiﬁed smaller GM in the temporal cortex in PNS patients with
no signiﬁcant GM differences with the non-PNS patients. This
suggests that patients, who in the course of their illness show PNS,
differ neurologically from those who do not show PNS in speciﬁc
neuroanatomical regions. This subtyping of whether biological
heterogeneity underlies observed clinical heterogeneity within the
patient group is merely an extension of the notion that biologi-
cal differences underlie observed behavioral differences between
patients and controls (Turetsky et al., 1995). Nevertheless, those
identiﬁed with PNS should be studied more closely as they can
offer better insights in the pathophysiology of primary negative
symptoms in schizophrenia and could aid in the development of
more effective treatments.
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